Skip to contentHome page Seeking Alpha - Power to InvestorsIsraelDec. 23, 2025 6:08 PM ETTeva Pharmaceutical Industries Limited (TEVA) Stock, TEVJF StockALVO, MDCLF, RHHBY, AMGN, SNY, NBIX, PFE, BMY, ALVOW, ROG:CA, ROCH:CA, PFE:CA, BMYMPALLKA Research3.14K FollowersCommentsTeva, the Israeli pharmaceutical giant, is reaching new heights, breaking the $30 mark.The rise in its share price reflects both the strengthening of its balance sheet and the rising sales of Austedo and Ajovy.So, sales of Ajovy totaled $169 million in Q3, up 22.5% year-on-year.However, Wall Street is beginning to reduce its stake in Teva.In this article,you'll learn why I no longer believe Teva's risk/reward is attractive.Prostock-Studio/iStock via Getty ImagesThe investment thesis I laid out in my first article about Teva Pharmaceutical (TEVA) has finally played out. At the time of that article, TEVA was fluctuating around $16.50-$17.00 and is now above $31.50.By the way, over the past twoThis article was written byALLKA Research3.14K FollowersWith over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landscape is marked by a commitment to delivering substantial returns and strategic insights to its clients. In a world filled with complexities, Allka Research thrives on simplifying investment strategies, ensuring accessibility for both seasoned investors and those just starting.Driven by an unwavering passion for empowering others financially, Allka Research seeks to share its wealth of knowledge through Seeking Alpha. Its mission is to contribute thought-provoking analyses and informed perspectives to the Seeking Alpha community. With a desire to demystify the intricacies of investing, Allka Research aims to inspire confidence in its readers, fostering a community of informed investors who can navigate the markets with intelligence and understanding. Join Allka Research on this exciting journey of discovery and wealth creation as it continues to unravel the secrets of the financial world on Seeking Alpha.Analyst’s Disclosure:I/we have a beneficial long position in the shares of ALVO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.CommentsTo ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.